Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Published in: European Journal of Nuclear Medicine and Molecular Imaging 8/2008

01-08-2008 | Original article

Biodistribution and radiation dosimetry of the A1 adenosine receptor ligand 18F-CPFPX determined from human whole-body PET

Authors: Hans Herzog, David Elmenhorst, Oliver Winz, Andreas Bauer

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 8/2008

Login to get access

Abstract

Purpose

18F-8-cyclopentyl-3-(3-fluoropropyl)-1-propylxanthine (18F-CPFPX) is a potent radioligand to study human cerebral A1 adenosine receptors and their neuromodulatory and neuroprotective functions with positron emission tomography (PET). The purpose of this study was to determine the biodistribution and the radiation dose of 18F-CPFPX by whole-body scans in humans.

Methods

Six normal volunteers were examined with 12 whole-body PET scans from 1.5 min to 4.5 h after injection. Volumes of interest were defined over all visually identifiable organs, i.e. liver, gallbladder, kidneys, small intestines, heart, and brain to obtain the organs’ volumes and time-activity curves (TACs). TACs were fitted with exponential functions, extrapolated, multiplied with the physical decay and normalized to injected activities so that the residence times could be computed as area under the curve. Radiation doses were calculated using the OLINDA/EXM software for internal dose assessment in nuclear medicine.

Results

The liver uptake shows peak values (decay-corrected) of up to 35% of the injected radioactivity. About 30% is eliminated by bladder voiding. The highest radiation dose is received by the gallbladder (136.2 ± 66.1 μSv/MBq), followed by the liver (84.4 ± 10.6 μSv/MBq) and the urinary bladder (78.3 ± 7.1 μSv/MBq). The effective dose was 17.6 ± 0.5 μSv/MBq.

Conclusions

With 300 MBq of injected 18F-CPFPX a subject receives an effective dose (ICRP 60) of 5.3 mSv. Thus the effective dose of an 18F-CPFPX study is comparable to that of other 18F-labelled neuroreceptor ligands.
Literature
1.
Dunwiddie TV, Masino SA. The role and regulation of adenosine in the central nervous system. Annu Rev Neurosci. 2001;24:31–55.PubMedCrossRef
2.
Fredholm BB, IJzerman AP, Jacobson KA, Klotz KN, Linden J. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev. 2001;53:527–52.PubMed
3.
Fastbom J, Pazos A, Probst A, Palacios JM. Adenosine A1 receptors in the human brain: A quantitative autoradiographic study. Neuroscience. 1987;22:827–39.PubMedCrossRef
4.
Svenningsson P, Hall H, Sedvall G, Fredholm BB. Distribution of adenosine receptors in the postmortem human brain: An extended autoradiographic study. Synapse. 1997;27:322–35.PubMedCrossRef
5.
Bauer A, Holschbach MH, Meyer PT, et al. In vivo imaging of adenosine A1 receptors in the human brain with [18F]CPFPX and positron emission tomography. Neuroimage. 2003;19:1760–9.PubMedCrossRef
6.
Haas HL, Selbach O. Functions of neuronal adenosine receptors. Naunyn Schmiedebergs Arch Pharmacol. 2000;362:375–81.PubMedCrossRef
7.
Bauer A, Langen KJ, Bidmon H, et al. 18F-CPFPX PET identifies changes in cerebral A1 adenosine receptor density caused by glioma invasion. J Nucl Med. 2005;46:450–4.PubMed
8.
Glass M, Faull RL, Bullock JY, et al. Loss of A1 adenosine receptors in human temporal lobe epilepsy. Brain Res. 1996;710:56–68.PubMedCrossRef
9.
Ulas J, Brunner LC, Nguyen L, Cotman CW. Reduced density of adenosine A1 receptors and preserved coupling of adenosine A1 receptors to G proteins in Alzheimer hippocampus: a quantitative autoradiographic study. Neuroscience. 1993;52:843–54.PubMedCrossRef
10.
Deckert J, Abel F, Kunig G, et al. Loss of human hippocampal adenosine A1 receptors in dementia: evidence for lack of specificity. Neurosci Lett. 1998;244:1–4.PubMedCrossRef
11.
Holschbach MH, Fein T, Krummeich C, et al. A1 adenosine receptor antagonists as ligands for positron emission tomography (PET) and single photon emission tomography (SPET). J Med Chem. 1998;41:555–63.PubMedCrossRef
12.
Holschbach MH, Olsson RA, Bier D, et al. Synthesis and evaluation of no-carrieradded 8-cyclopentyl-3-(3-[(18)F]fluoropropyl)-1-propylxanthine ([(18)F] CPFPX): a potent and selective A(1)-adenosine receptor antagonist for in vivo imaging. J Med Chem. 2002;45:5150–6.PubMedCrossRef
13.
Herzog H, Boy C, Holschbach M, et al. Cerebral Kinetics of the A1 Adenosine Receptor Antagonist [18F]CPFPX Measured in Non-Human Primates. J Cereb Blood Flow Metab. 2003;23(Suppl.1):690.
14.
Meyer PT, Bier D, Holschbach MH, et al. Quantification of cerebral A1 adenosine receptors in humans using [18F]CPFPX and PET. J Cereb Blood Flow Metab. 2004;24:323–33.PubMedCrossRef
15.
Meyer PT, Elmenhorst D, Bier D, et al. Quantification of cerebral A1 adenosine receptors in humans using [18F]CPFPX and PET: an equilibrium approach. Neuroimage. 2005;24:1192–204.PubMedCrossRef
16.
Meyer PT, Elmenhorst D, Zilles K, Bauer A. Simplified quantification of cerebral A1 adenosine receptors using [18F]CPFPX and PET: analyses based on venous blood sampling. Synapse. 2005;55(4):212–23.PubMedCrossRef
17.
Elmenhorst D, Meyer PT, Winz OH, et al. Sleep deprivation increases A1 adenosine receptor binding in the human brain: a positron emission tomography study. J Neurosci. 2007;27:2410–5.PubMedCrossRef
18.
Boy C, Meyer PT, Kircheis G, et al. Cerebral A1 adenosine receptors (A1AR) in liver cirrhosis. Eur J Nucl Med Mol Imag. (paper accepted).
19.
Matusch A, Meyer PT, Bier D, et al. Metabolism of the A1 adenosine receptor PET ligand [18F]CPFPX by CYP1A2: implications for bolus/infusion PET studies. Nucl Med Biol. 2006;33:891–8.PubMedCrossRef
20.
Herzog H, Holschbach M, Boy C, et al. Biodistribution and radiation dose of the new A1 adenosine receptor antagonist [F-18] CPFPX in mice and baboon. J Nucl Med. 1998;39(5):188P.
21.
Brix G, Zaers J, Adam L, et al. Performance evaluation of a whole-body PET Scanner using the NEMA protocol. J Nucl Med. 1997;38:1614–23.PubMed
22.
Lu JQ, Ichise M, Liow JS, Ghose S, Vines D, Innis RB. Biodistribution and radiation dosimetry of the serotonin transporter ligand 11C-DASB determined from human whole-body PET. J Nucl Med. 2004;45:1555–9.PubMed
23.
Slifstein M, Hwang DR, Martinez D, et al. Biodistribution and radiation dosimetry of the dopamine D2 ligand 11C-raclopride determined from human whole-body PET. J Nucl Med. 2006;47:313–9.PubMed
24.
Nye JA, Schuster DM, Yu W, Camp VM, Goodman MM, Votaw JR. Biodistribution and radiation dosimetry of the synthetic nonmetabolized amino acid analogue anti-18F-FACBC in humans. J Nucl Med. 2007;48:1017–20.PubMedCrossRef
25.
Hoffman EJ, Huang SC, Phelps ME, Kuhl DE. Quantitation in positron emission computed tomography: 4. Effect of accidental coincidences. J Comput Assist Tomogr. 1981;5:391–400.PubMedCrossRef
26.
International Commission on Radiological Protection. Limits for intakes of radionuclides by workers. ICRP Publication 30 Part 1 (Oxford, UK: Pergamon Press), 1979.
27.
Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005;46:1023–7.PubMed
28.
Herzog H, Zilken H, Niederbremer A, Friedrich W, Müller-Gärtner HW. Calculation of residence times and radiation doses using the standard PC-software Excel. Eur J Nucl Med. 1997;24:1514–21.PubMedCrossRef
29.
Cloutier RJ, Smith SA, Watson EE, et al. Dose to the fetus from radionuclides in the bladder. Health Physics. 1973;25:147–61.PubMedCrossRef
30.
International Commission on Radiological Protection. 1990 Recommendations of the International Commission on Radiological Protection. ICRP Publication 60. New York: Pergamon Press; 1991.
31.
International Commission on Radiological Protection. Report of the task group on reference man. ICRP Publication 23. Oxford: Pergamon Press; 1975.
32.
Food and Drug Administration. Title 21 CFR 361.1, Radioactive Drugs for Certain Research Uses. 4–1–01 ed. Washington, DC: National Archives and Records Administration; 2001:300–305.
33.
Siegel JA, Thomas SR, Stubbs JB, Stabin MG, Hays MT, Koral KF, et al. MIRD pamphlet no. 16: Techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. J Nucl Med. 1999;40:37S–61S.PubMed
34.
Kessler RM, Mason NS, Jones C, Ansari MS, Manning RF, Price RR. [18F] N-ally-5-fluorproplepidepride (fallypride): radiation dosimetry, quantification of striatal and extrastriatal dopamine receptors in man. Neuroimage. 2000;6:S32.
35.
Herzog H, Coenen HH, Kuwert T, Langen KJ, Feinendegen LE. Quantitation of the whole-body distribution of PET radiopharmaceuticals: Applied to 3-N-([18F]fluoroethyl)spiperone. Eur J Nucl Med. 1990;16:77–83.PubMedCrossRef
Metadata
Title
Biodistribution and radiation dosimetry of the A1 adenosine receptor ligand 18F-CPFPX determined from human whole-body PET
Authors
Hans Herzog
David Elmenhorst
Oliver Winz
Andreas Bauer
Publication date
01-08-2008
Publisher
Springer-Verlag
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 8/2008
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-008-0753-x

Other articles of this Issue 8/2008

European Journal of Nuclear Medicine and Molecular Imaging 8/2008 Go to the issue

Original Article

[18F]Fluorinated estradiol derivatives for oestrogen receptor imaging: impact of substituents, formulation and specific activity on the biodistribution in breast tumour-bearing mice

Original article

Effects of AV delay programming on ventricular resynchronisation: role of radionuclide ventriculography

Letter to the Editor

Improving outcome after positive interim PET in advanced Hodgkin’s disease: reality vs expectation

Original Article

Evaluation of a decision support system for interpretation of myocardial perfusion gated SPECT

Original Article

99mTc sestamibi myocardial perfusion scintigraphy with the novel use of metamizol for the detection of perfusion reversibility

Guidelines

Guidelines for 18F-FDG PET and PET-CT imaging in paediatric oncology